Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis

27 Sept 2019

Abstract excerpt

Abstract The tumor microenvironment (TME) is a key determinant of metastatic efficiency. We performed a quantitative high-throughput screen (qHTS) of diverse medicinal chemistry tractable scaffolds (44,420 compounds) and pharmacologically active small molecules (386 compounds) using a layered organotypic, robust assay representing the ovarian cancer metastatic TME. This 3D model contains primary human mesothelial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Lipids, and Metabolism
Share to Cytokine Signaling Pathways and Interactions
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31562255
DOI: 10.1158/1535-7163.mct-19-0052

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 11 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer MetastasisPMID 31562255Read ↗

Generation of an in vitro 3D multicellular culture model of ovarian high-grade serous carcinomaSemantic proximity Read ↗

Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screeningSemantic proximity Read ↗

Whole-Process 3D ECM-Encapsulated Organoid-Based Automated High-Throughput Screening Platform Accelerates Drug Discovery for Rare DiseasesSemantic proximity Read ↗

Comprehensive drug efficacy data for mucinous ovarian carcinoma using a novel and extensive biobank of patient-derived organoid modelsSemantic proximity Read ↗

In vitro drug testing using patient-derived ovarian cancer organoidsSemantic proximity Read ↗

Multicompartmentalized Microvascularized Tumor-on-a-Chip to Study Tumor-Stroma Interactions and Drug Resistance in Ovarian CancerSemantic proximity Read ↗

High‐throughput screening in colorectal cancer tissue‐originated spheroidsSemantic proximity Read ↗

From 2D Drug Screening to Predictive Pharmacology: Redefining Preclinical Models in OncologySemantic proximity Read ↗

Constructing a co-culture model of cancer-associated fibroblasts and ovarian cancer organoids and studying mechanisms of drug resistanceSemantic proximity Read ↗

An <i>In Vitro</i> Vascularized Micro-Tumor Model of Human Colorectal Cancer Recapitulates <i>In Vivo</i> Drug ResponsesSemantic proximity Read ↗

High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific In Silico Models of Metastatic Colorectal CancerSemantic proximity Read ↗

Targeting metabolic fluxes reverts metastatic transitions in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.